HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach July 8, 2025
First Patient Dosed with Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab July 1, 2025
Early-Stage Clinical Data and Anti-Proliferative Results Reported for APR-1051 in HPV+ HNSCC July 1, 2025
FDA Approves KEYTRUDA for PD-L1+ Resectable Locally Advanced SCCHN as Neoadjuvant and Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent June 17, 2025
FAILED TRIAL: ASPEN-03 and ASPEN-04 Ph 2 Trials of Evorpacept + Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints April 30, 2025
Multikine Confirmatory Ph 3 Trial in newly diagnosed locally advanced head and neck cancer patients to be Initiated March 18, 2025
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for HNSCC March 18, 2025
Head and Neck Cancer Registration Study Protocol Clears FDA Review; in Talks with Potential Partners Interested in Commercialization of Multikine March 18, 2025
JAMA Study suggests that Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression March 18, 2025
VERSATILE-003 Ph 3 Trial of Versamune HPV in HPV16-Positive Head and Neck Cancer Initiated March 11, 2025
Confirmatory Registration Study for Multikine in PD-L1 low newly diagnosed head and neck cancer patients in final stage of start-up preparations March 11, 2025
FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer March 4, 2025
FDA Grants Priority Review to KEYTRUDA + SOC as Perioperative Treatment for Resectable Locally Advanced SCCHN; PDUFA: Jun 23, 2025 March 4, 2025
Petosemtamab granted Breakthrough Therapy designation by the US FDA for 1L PD-L1 positive head and neck squamous cell carcinoma February 25, 2025
ASCO-GU 2025: CRB-701 (SYS6002) Demonstrates Encouraging Safety and Broader Efficacy in Ph 1 Study February 19, 2025
First Patients Enrolled in FORTIFI-HN01, Ph 2/3 Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma February 17, 2025
Positive interim Alpha DaRT data from multiple clinical trials in pancreatic cancer, a combination study with pembrolizumab in patients with recurrent unresectable or metastatic HNSCC, and other clinical trials announced February 4, 2025
Global Ph 3 Trial of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab for 1L Recurrent Head and Neck Cancer initiated January 28, 2025
